Navigation Links
AIDS drug shown to prevent HIV in multinational trial of HIV-negative gay men
Date:11/23/2010

Chicago, November 23, 2010 Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today. Data from this trial, called iPrEx, indicated an estimated 43.8% reduction of new HIV infections among men who took an antiretroviral tablet daily to prevent HIV, compared to those who took a placebo pill.

"This discovery alters the HIV prevention landscape forever. While this level of efficacy is relatively strong, PrEP is not quite ready for prime time and work remains before this strategy is rolled out. However, we are thrilled to have a new prevention option beyond male and female condoms visible on the horizon," said Jim Pickett, Director of Advocacy at AIDS Foundation of Chicago and Chair of IRMA International Rectal Microbicide Advocates.

The iPrEx trial evaluated the safety and efficacy of the antiretroviral (ARV) drug TDF/FTC (brand name Truvada) taken once daily for HIV prevention among HIV-negative gay men, transgender women, and other men who have sex with men (MSM).

The participants, 2,499 in all, included individuals from Peru, Ecuador, Brazil, South Africa, Thailand and the United States. Half the men were randomized into the active arm that received Truvada, and the other half were randomized into the placebo arm and received a look-alike pill with no active ingredient. The participants and the researchers did not know who was in either arm. Enrollment for the trial began in June 2007 and was completed in December 2009. The primary analysis of the results released today includes participants who were followed until May 1, 2010, or for an average of 14 months.

Each participant was tested for HIV at monthly trial visits and given intensive pre-and-post test counseling. Additionally, they were regularly screened for sexually transmitted infections and received condoms, making up a very robus
'/>"/>

Contact: Jim Pickett
jpickett@aidschicago.org
773-600-6407
International Rectal Microbicide Advocates
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Scented consumer products shown to emit many unlisted chemicals
2. Valproic acid shown to halt vision loss in patients with retinitis pigmentosa
3. Promising results shown for kidney cancer drug
4. UB specialized exercise regimen shown to relieve prolonged concussion symptoms
5. BBS proteins shown to run an export business that protects cilia
6. Carvedilol shown to have unique characteristics among beta blockers
7. Widely used virus assay shown unreliable when compared to other methods
8. Twin nanoparticle shown effective at targeting, killing breast cancer cells
9. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
10. Ultrasound shown to exert remote control of brain circuits
11. To prevent inbreeding, flowering plants have evolved multiple genes, research reveals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... A new systematic assessment of malnutrition, created by ... health care providers in diagnosis and treatment. Up ... facilities are estimated to be malnourished, according to Gordon ... Although malnutrition is widespread, confusion exists in the clinical ...
... discovered an Achilles heel within our cells that bacteria are ... The researchers say their findings could lead to the development ... has led to resistance. University of Manchester researchers studied ... that can cause listeriosis in humans when digested and ...
... Samuel M. Young, Jr., PhD, research group leader ... received his first grant from The Michael J. Fox ... enable Dr. Young and colleagues to develop a technology ... research potential treatments that target LRRK2, a Parkinson,s-related gene. ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 2Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools 3
(Date:2/27/2015)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... that it will be presenting at CALBIO 2015 at ... at 3pm PST. Patrick Lucy, chief business officer of ... state of the biosimilar industry landscape entitled The ... more information on CALBIO 2015 and The Evolving ...
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the industry ... and internationally, intends to open a full service medical ... Mexico , bringing advanced scientific tools and methodology ... Steep Hill is currently the only laboratory licensed ... potency and contaminant testing in order to meet the ...
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... against billions in pest losses annually , ... St. Louis, MO (PRWEB) ... Divergence, Inc. , has received more than $1.2 million in research ... (NSF) to further the company,s work on biotech traits for lesion nematode ...
... CINCINNATI, April 28 Kendle (Nasdaq: KNDL ... announced Karl "Buzz" Brenkert III, Senior Vice President, Chief ... effective May 6, 2009. Brenkert has served as CFO ... Senior Vice President and CFO is Keith A. Cheesman, ...
... (LSE: SHP, NASDAQ:, SHPGY ), the global specialty biopharmaceutical company, announces that at its,Annual General Meeting today, all ... , ... For* Against Withheld**, 1. ... together with the, ...
Cached Biology Technology:Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn 2Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn 3Kendle Announces Departure of Senior Vice President and CFO Karl 'Buzz' Brenkert III; Appoints Keith A. Cheesman as Successor 2Shire plc: Results of the Annual General Meeting Held on April 28, 2009 2
... Clone/PAD: ZMD.473. Immunogen: Synthetic ... of the mouse junctophilin-2. Specificity: ... Reactivity: Mouse (positive controls: mouse skeletal ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
UCP1/2/3 (FL-307)...
... Proliferation Kit, For 100 slides. Immunocytochemistry.Sample ... in vitro tissue labeling.Recommended cell number: ... (labeling 1-2 hours).Store at 2-8 C ... Category: Drug Screening & Cellular Assays, ...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
Biology Products: